| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 01/10/2007 | CN1893981A Methods and compositions for treatment of interferon-resistant tumors |
| 01/10/2007 | CN1893980A Novel GLP-1 analogues linked to albumin-like agents |
| 01/10/2007 | CN1893978A Combinations for HCV treatment |
| 01/10/2007 | CN1893975A Medicament comprising inhibitors of long pentraxin ptx3 |
| 01/10/2007 | CN1893969A Medicament comprising ptx3, alone or in combination with tsg-6, for treating degenerative diseases of cartilage and bone and treating female infertility |
| 01/10/2007 | CN1893968A Regulation of sperm function |
| 01/10/2007 | CN1893967A Leukocyte internalized peptide-drug conjugates |
| 01/10/2007 | CN1893966A Replikin peptides in rapid replication of glioma cells and in influenza epidemics |
| 01/10/2007 | CN1893961A Biologically active blood serum obtained by electroshock |
| 01/10/2007 | CN1893923A Self-nanoemulsifying oily formulation for the administration of poorly water-soluble drugs |
| 01/10/2007 | CN1893919A Endoparasiticidal agents for topical application |
| 01/10/2007 | CN1893911A Formula including tetrapeptide and tripeptide mixture |
| 01/10/2007 | CN1893838A Peptides having an ace inhibiting effect |
| 01/10/2007 | CN1893821A 受体 Acceptor |
| 01/10/2007 | CN1891829A Alpha (1,3) galactosyl transferase recombinant vector, virosome and its preparation and use |
| 01/10/2007 | CN1891819A Method for producing asparaginase by Erwinia fermentation |
| 01/10/2007 | CN1891717A Chemical modification method of endostatin and its use |
| 01/10/2007 | CN1891714A Ligand for herpes simplex virus entry mediator and methods of use |
| 01/10/2007 | CN1891713A Virulence genes and proteins, and their use |
| 01/10/2007 | CN1891711A Method for preparing physiological active polypeptide of deer placenta |
| 01/10/2007 | CN1891294A Pharmaceutical use of recombinant staphylokinase for treating high viscosity blood disease |
| 01/10/2007 | CN1891234A Leech polypeptide lyophilized powder injection preparation and its preparing method |
| 01/10/2007 | CN1891222A Medicinal composition containing enalapril or genazepril and sotalol |
| 01/10/2007 | CN1294255C Toxicide enzyme with aflatoxin activity conversion activity and gene for coding the enzyme |
| 01/10/2007 | CN1294143C Nucleotide and amino acid sequences of oocyte factors for altering ovarian follicular growth in vivo or in vitro |
| 01/10/2007 | CN1293922C Application of HGF gene |
| 01/10/2007 | CN1293916C Stable insulin formulations |
| 01/10/2007 | CN1293915C Method for reducing calcified plaque buildup and cellular malfunction and for balancing ionic calcium |
| 01/09/2007 | US7161314 Motor control apparatus having current supply phase correction |
| 01/09/2007 | US7161033 E.g., 2S [[(N-methylamino)acetyl]amino]-N-[2R-hydroxy-3-[[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl]-3,3-dimethyl-butanamide; in particular as inhibitors of HIV protease |
| 01/09/2007 | US7160995 DNA encoding anti-TNF antibodies and peptides |
| 01/09/2007 | US7160993 Nucleic acids encoding PRO4400 polypeptides |
| 01/09/2007 | US7160992 Amino-modified polysaccharides and methods of generating and using same |
| 01/09/2007 | US7160991 Vascular endothelial growth factor polypeptides |
| 01/09/2007 | US7160990 Immunoglobulin for use in detection and prevention staphylococcus infections |
| 01/09/2007 | US7160987 Administering a monoclonal antibodie, that bind specifically to one or more preselected CD45R leukocyte antigens, including CD45RB epitope for prevention or reversal of transplant rejection or therapy of autoimmune diseases |
| 01/09/2007 | US7160986 BCL-xγ, a novel BCL-x isoform, and uses related thereto |
| 01/09/2007 | US7160985 For therapy of diabetes |
| 01/09/2007 | US7160984 Process for preparing glycopeptide derivatives |
| 01/09/2007 | US7160983 1((-4-oxo- N2-(12-methyl-1-oxotetradecyl) L-ornithine) 4-(4-(4- hydroxyphenyl)-L-threonine)-5-L-serine-echinocandin B, and other derivatives |
| 01/09/2007 | US7160981 Peptide antagonists of DP transcription factors |
| 01/09/2007 | US7160924 polyacetal-protein conjugates which demonstrate advantages in bioavailability and biocompatibility compared to unconjugated proteins, without any undesirable side effects e.g., kidney vacuole formation |
| 01/09/2007 | US7160904 Nicotine in therapeutic angiogenesis and vasculogenesis |
| 01/09/2007 | US7160899 Use of at least one compound with neurotrophic activity and at least one adenosine A2A receptor antagonist for the manufacture of a medicament for the treatment, prevention or alleviation of Parkinson's disease in a subject |
| 01/09/2007 | US7160870 Thrombopoietin mimetics |
| 01/09/2007 | US7160868 Nr-CAM gene, nucleic acids and nucleic acid products for therapeutic and diagnostic uses for tumors |
| 01/09/2007 | US7160864 Methods for production of growth-promoting proteins and peptides for kidney epithelial cells |
| 01/09/2007 | US7160863 Fusion protein contains amino acid sequence with 9 to 13 residues of arginine; antagonist of Nuclear Factor Activated T cell (NFAT); short effectiveness and no side effects or antigenicity; signal sequence, immunosuppressants, biodrugs |
| 01/09/2007 | US7160862 A mixture of polypeptides, as calcium binding protein for reducing bone loss and reducing renal phosphate excretion; biodrug for treating bone disorders; injectable solution or dispersed in toothpaste or a mouthwash or gum patch |
| 01/09/2007 | US7160861 Methods of inducing IL-10 production |
| 01/09/2007 | US7160860 Biosynthesis inhibition of oestrogen in an oestrogen-dependent breast tumor by administering a antitumor biodrug, Sant 7; aromatase, oestrone sulphatase, or oestradiol dehydrogenase inhibitors |
| 01/09/2007 | US7160859 administering compounds/agents that inhibit Mst1 or the Mst1 kinase pathway such as Caspase 3 inhibitors; assay system for screening potential compounds or agents effective to modulate Mst1 activity; transgenic animal wherein Mst1 expression or activity is enhanced |
| 01/09/2007 | US7160857 Methods for increasing schwann cell survival |
| 01/09/2007 | US7160856 Such as alpha-O-linked glycopeptides with clustered glycodomains which are useful as anticancer agents |
| 01/09/2007 | US7160855 Enhancement of iron chelation therapy |
| 01/09/2007 | US7160854 Binaphthyl peptidomimetics for treating vancomycin resistant Staphylococcus aureas infections |
| 01/09/2007 | US7160853 Peptides (such as terlipressin) for treatment of hypovolaemia/hypotension; for management of ascites in cirrhotic individuals |
| 01/09/2007 | US7160726 Compositions comprising conditioned cell culture media and uses thereof |
| 01/09/2007 | US7160725 Hedgehog signaling promotes the formation of three dimensional cartilage matrices |
| 01/09/2007 | US7160722 Master bone formation transcription factor: compositions and methods of use |
| 01/09/2007 | US7160720 Nucleotide sequences coding enzymetic polypeptide for use in the treatment of cardiovascular disorders |
| 01/09/2007 | US7160695 For therapy of inflammatory disease; disorder associated with inappropriate apoptosis |
| 01/09/2007 | US7160694 Nucleic acids encoding TANGO405 and functional fragments and uses thereof |
| 01/09/2007 | US7160693 Human hydrolase family members and uses thereof |
| 01/09/2007 | US7160685 Peptides having SEQ ID NO: 2 with immunogenic epitopes activating CD8+ class I major histocompatibility complex restricted cytotoxic T-lymphocytes for patients harboring latent HCMV infection in the absence of active viral replication; using enriched antigen presenting cells; vaccines |
| 01/09/2007 | US7160547 Comprising a pharmaceutically acceptable carrier and a peptide immunogen for eliciting an immune response in a subject and having at least one streptolysin S epitope |
| 01/09/2007 | US7160546 Immunizing an animal with a polypeptide; recovering an antibody which binds polypeptide |
| 01/09/2007 | US7160545 Useful for treatment and prevention of prostate cancer; is recognized by cytotoxic T lymphocytes |
| 01/09/2007 | US7160544 Method of vaccinating vertebrates |
| 01/09/2007 | US7160543 Tumor necrosis factor nucleic acid; antiinflammatory agents, autoimmune disease, viricides, parasiticides, central nervous system disorders; anti-TNF peptides inhibit and/or neutralize epitopes of human tumor necrosis factor-alpha |
| 01/09/2007 | US7160542 Method of treating psoriasis using human anti-TNF antibodies and fragments |
| 01/09/2007 | US7160541 Modified polypeptides stabilized in a desired conformation and methods for producing same |
| 01/09/2007 | US7160540 Methods for detecting activity of clottings factors |
| 01/09/2007 | US7160539 Altering T cell mediated immunity comprising altering local extracellular concentrations of tryptophan and tryptophan metabolites |
| 01/09/2007 | CA2364617C Method for the reductive amination of polysaccharides |
| 01/09/2007 | CA2308520C Strictly alternating poly(alkylene oxide ether) copolymers |
| 01/09/2007 | CA2295177C Drug targeting system, method of its preparation and its use |
| 01/09/2007 | CA2294172C Pharmaceutical composition in form of solid lipidic microparticles suitable to parenteral administration |
| 01/09/2007 | CA2286190C Gnrh antagonists being modified in positions 5 and 6 |
| 01/09/2007 | CA2263129C Mammalian cell surface antigens; related reagents |
| 01/09/2007 | CA2245099C Immortal human prostate epithelial cell lines and clones and their applications in the research and therapy of prostate cancer |
| 01/09/2007 | CA2232325C Tumor rejection antigens presented by hla-b44 molecules, and uses thereof |
| 01/09/2007 | CA2194352C Diagnostic methods and compositions relating to the proteoglycan proteins of cartilage breakdown |
| 01/09/2007 | CA2168268C Aids and sle prophylactics |
| 01/09/2007 | CA2162732C Use of modified tall-104 cells to treat cancer and viral diseases |
| 01/09/2007 | CA2095153C Genetic modification of endothelial cells |
| 01/08/2007 | CA2528635A1 Tumor treatment using beta-sheet peptides and radiotherapy |
| 01/07/2007 | CA2551622A1 Dietary supplement for enhancing skeletal muscle mass, decreasing muscleprotein degradation, downregulation of muscle catabolism pathways, and decreasing catabolism of muscle cells |
| 01/04/2007 | WO2007002899A2 Therapeutic applications of aminolevulinate synthase |
| 01/04/2007 | WO2007002811A2 Methods and compositions for treating melanoma |
| 01/04/2007 | WO2007002594A1 Cosmetic compositions and methods using transforming growth factor-beta mimics |
| 01/04/2007 | WO2007002482A1 Method for identifying modulators of rufy2 useful for treating alzheimer's disease |
| 01/04/2007 | WO2007002469A2 Therapeutic compositions and methods using transforming growth factor-beta mimics |
| 01/04/2007 | WO2007002306A1 Compositions and methods for nerve regeneration |
| 01/04/2007 | WO2007002294A2 Composition for enhancing cellular energy |
| 01/04/2007 | WO2007002222A2 Psma antibody-drug conjugates |
| 01/04/2007 | WO2007002191A2 Methods for the preparation of 9-deazapurine derivatives |
| 01/04/2007 | WO2007002163A2 Production of recombinant selenoprotein mutants with enhanced catalytic activity |
| 01/04/2007 | WO2007002145A2 Lysozyme-based food stuff |
| 01/04/2007 | WO2007002131A2 Galk1s as modifiers of the pten/akt pathway and methods of use |